ReviewAlzheimer's research & therapy2013
Dominantly Inherited Alzheimer Network: facilitating research and clinical trials.
Review in Alzheimer's research & therapy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06384573 (The Dominantly Inherited Alzheimer Network Trials Unit), which is not on this map. Cited by 96 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) Amyloid Removal Trial (ART): A Phase IIIb/IV Open-Label Study of Lecanemab to Evaluate Prevention and Progression of Dominantly Inherited Alzheimer's Disease
Who cites it
96 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis.Neurology · 2014Pooled it
- Regional effects of gantenerumab on neuroimaging biomarkers in the DIAN-TU-001 trial.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Trial
- Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trial.The Lancet. Neurology · 2025Trial
- A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease.Nature medicine · 2021Trial
- APOE and genetic risk variants influence Alzheimer's disease onset in carriers of an extra copy of APP, with and without Down syndrome.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Effect of Cognitive Reserve on Age at Symptom Onset and Cognitive Decline in Individuals With Dominantly Inherited Alzheimer Disease.Neurology · 2026Article
- Critical and non-critical connections not differently associated with either Alzheimer's disease or vascular pathologies.medRxiv : the preprint server for health sciences · 2026Article
- Cortical asymmetry in autosomal dominant Alzheimer's disease progression.Brain communications · 2026Article
- Beyond Alzheimer's disease-translating biomarker insights across CNS diseases.Science translational medicine · 2025Review
- The landscape of autosomal-dominant Alzheimer's disease: global distribution and age of onset.Brain : a journal of neurology · 2025Article
- Sample size estimates for biomarker-based outcome measures in clinical trials in autosomal dominant Alzheimer's disease.The journal of prevention of Alzheimer's disease · 2025Article
- Functional near-infrared spectroscopy and vagus somatosensory evoked potentials add to the power of established parameters such as poor cognitive performance, dsyosmia and APOe genotype to predict cognitive decline over 8 years in the elderly.Journal of neural transmission (Vienna, Austria : 1996) · 2025Observational
- Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU Trial.medRxiv : the preprint server for health sciences · 2025Article
- In Vivo Tau and Neurodegeneration Imaging in a Family With the Presenilin 1 Met146Leu Pathogenic Variant.Neurology · 2024Article
- Clinical and research application of fluid biomarkers in autosomal dominant Alzheimer's disease and Down syndrome.EBioMedicine · 2024Review
- Beyond the usual suspects: multi-factorial computational models in the search for neurodegenerative disease mechanisms.Translational psychiatry · 2024Review
- Genetic and multi-omic resources for Alzheimer disease and related dementia from the Knight Alzheimer Disease Research Center.Scientific data · 2024Article
- Advancements in dementia research, diagnostics, and care in Latin America: Highlights from the 2023 Alzheimer's Association International conference satellite symposium in Mexico City.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Review
- Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU): Trial Satisfaction and Attitudes towards Future Clinical Trials.The journal of prevention of Alzheimer's disease · 2024Article
- Pathogenic variants in the Longitudinal Early-onset Alzheimer's Disease Study cohort.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2023Review
36 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The Dominantly Inherited Alzheimer Network (DIAN) is an international registry of individuals at risk for developing autosomal dominant Alzheimer's disease (AD). Its primary aims are to investigate the temporal ordering of AD pathophysiological changes that occur in asymptomatic mutation carriers and to identify those markers that herald the transition from cognitive normality to symptomatic AD. DIAN participants undergo longitudinal evaluations, including clinical and cognitive assessments and measurements of molecular and imaging AD biomarkers. This review details the unique attributes of DIAN as a model AD biomarker study and how it provides the infrastructure for innovative research projects, including clinical trials. The recent design and launch of the first anti-amyloid-beta secondary prevention trial in AD, led by the related DIAN Trials Unit, also are discussed.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.